Do analysts prefer IDHC or DXRX?

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integrated Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer ABDX or DXRX?

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer DXRX or GDR?

Diaceutics currently has a consensus price target of GBX 205.33, indicating a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, research analysts plainly believe Diaceutics is more favorable than genedrive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 genedrive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, DXRX or GDR?

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £38.44M 3.19 -£2.84M £0.11 1,318.18 genedrive £929K 22.04 -£21.22M -£0.79 N/A

Is DXRX or GDR more profitable?

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics 0.25% 0.25% -6.06% genedrive -500.75% -1,044.57% -74.09%

Do analysts prefer YGEN or DXRX?

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Yourgene Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate VRCI or DXRX?

Diaceutics has a consensus price target of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Verici Dx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verici Dx 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, VRCI or DXRX?

Diaceutics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verici Dx £1.91M 3.16 -£6.56M -£2.90 N/A Diaceutics £38.44M 3.19 -£2.84M £0.11 1,318.18

Is VRCI or DXRX more profitable?

Diaceutics has a net margin of 0.25% compared to Verici Dx's net margin of -468.31%. Diaceutics' return on equity of 0.25% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -468.31% -178.37% -26.14% Diaceutics 0.25% 0.25% -6.06%

Diaceutics (DXRX) Competitors

GBX 145 +0.50 (+0.35%)

As of 06/24/2026 12:23 PM Eastern

Compare

DXRX vs. IDHC, ABDX, GDR, YGEN, and VRCI

Should you buy Diaceutics stock or one of its competitors? MarketBeat compares Diaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Diaceutics include Integrated Diagnostics (IDHC), Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), and Verici Dx (VRCI). These companies are all part of the "diagnostics & research" industry.

How does Diaceutics compare to Integrated Diagnostics?

Integrated Diagnostics (LON:IDHC) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Integrated Diagnostics has a net margin of 17.46% compared to Diaceutics' net margin of 0.25%. Integrated Diagnostics' return on equity of 42.26% beat Diaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integrated Diagnostics	17.46%	42.26%	9.69%
Diaceutics	0.25%	0.25%	-6.06%

In the previous week, Integrated Diagnostics had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Diaceutics. Integrated Diagnostics' average media sentiment score of 1.17 beat Diaceutics' score of 0.00 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Integrated Diagnostics	Positive
Diaceutics	Neutral

Integrated Diagnostics has a beta of 0.376, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.893, indicating that its stock price is 11% less volatile than the broader market.

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Integrated Diagnostics is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated Diagnostics	£8.35B	0.00	£4.01T	£250.03	0.00
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

7.7% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 32.3% of Diaceutics shares are owned by institutional investors. 49.7% of Integrated Diagnostics shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Integrated Diagnostics beats Diaceutics on 9 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	2.89	-£796.37K	-£0.81	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
Diaceutics	0.25%	0.25%	-6.06%

In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
Abingdon Health	Neutral
Diaceutics	Neutral

Abingdon Health has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.893, indicating that its stock price is 11% less volatile than the broader market.

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.7% of Abingdon Health shares are owned by institutional investors. Comparatively, 32.3% of Diaceutics shares are owned by institutional investors. 8.0% of Abingdon Health shares are owned by company insiders. Comparatively, 26.3% of Diaceutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Diaceutics beats Abingdon Health on 13 of the 14 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

Diaceutics (LON:DXRX) and genedrive (LON:GDR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18
genedrive	£929K	22.04	-£21.22M	-£0.79	N/A

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled genedrive'saverage media sentiment score.

Company	Overall Sentiment
Diaceutics	Neutral
genedrive	Neutral

Diaceutics has a beta of 0.893, indicating that its stock price is 11% less volatile than the broader market. Comparatively, genedrive has a beta of 1.024, indicating that its stock price is 2% more volatile than the broader market.

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
genedrive	-500.75%	-1,044.57%	-74.09%

32.3% of Diaceutics shares are owned by institutional investors. Comparatively, 0.1% of genedrive shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by insiders. Comparatively, 29.0% of genedrive shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Diaceutics currently has a consensus price target of GBX 205.33, indicating a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, research analysts plainly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Diaceutics beats genedrive on 11 of the 14 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

23.3% of Yourgene Health shares are owned by institutional investors. Comparatively, 32.3% of Diaceutics shares are owned by institutional investors. 64.4% of Yourgene Health shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
Yourgene Health	Neutral
Diaceutics	Neutral

Diaceutics has a consensus target price of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Diaceutics has a net margin of 0.25% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of 0.25% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Diaceutics	0.25%	0.25%	-6.06%

Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.893, meaning that its stock price is 11% less volatile than the broader market.

Diaceutics has higher revenue and earnings than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Summary

Diaceutics beats Yourgene Health on 12 of the 13 factors compared between the two stocks.

How does Diaceutics compare to Verici Dx?

Verici Dx (LON:VRCI) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

15.7% of Verici Dx shares are held by institutional investors. Comparatively, 32.3% of Diaceutics shares are held by institutional investors. 1.2% of Verici Dx shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Diaceutics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£1.91M	3.16	-£6.56M	-£2.90	N/A
Diaceutics	£38.44M	3.19	-£2.84M	£0.11	1,318.18

Diaceutics has a consensus price target of GBX 205.33, suggesting a potential upside of 41.61%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than Verici Dx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verici Dx	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Verici Dx had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.00 beat Verici Dx's score of -1.59 indicating that Diaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Verici Dx	Very Negative
Diaceutics	Neutral

Verici Dx has a beta of 1.258, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Diaceutics has a beta of 0.893, suggesting that its stock price is 11% less volatile than the broader market.

Diaceutics has a net margin of 0.25% compared to Verici Dx's net margin of -468.31%. Diaceutics' return on equity of 0.25% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-468.31%	-178.37%	-26.14%
Diaceutics	0.25%	0.25%	-6.06%

Summary

Diaceutics beats Verici Dx on 14 of the 16 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Diagnostics & Research Industry	Medical Sector	LON Exchange
Market Cap	£122.71M	£594.72M	£6.74B	£2.77B
Dividend Yield	N/A	3.34%	2.68%	6.16%
P/E Ratio	1,318.18	78.33	25.39	366.61
Price / Sales	3.19	625.79	530.17	86,103.13
Price / Cash	3.12	11.42	45.29	27.87
Price / Book	3.16	3.37	10.76	7.85
Net Income	-£2.84M	£334.07B	£3.56B	£5.89B
7 Day Performance	N/A	0.71%	0.98%	-0.98%
1 Month Performance	-12.12%	-3.64%	0.78%	-0.79%
1 Year Performance	28.89%	3.84%	30.24%	70.20%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	N/A	GBX 145 +0.3%	GBX 205.33 +41.6%	+26.1%	£122.71M	£38.44M	1,318.18	151
IDHC Integrated Diagnostics	N/A	GBX 0.53 -0.4%	N/A	+43.7%	£309.27M	£8.35B	0.00	6,692	News Coverage
ABDX Abingdon Health	N/A	GBX 12.06 -4.3%	N/A	+69.0%	£31.64M	£9.57M	N/A	84	Gap Down
GDR genedrive	N/A	GBX 1.24 +5.5%	N/A	-13.5%	£18.87M	£929K	N/A	43	Positive News Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and VRCI

How does Diaceutics compare to Integrated Diagnostics?

Summary

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to genedrive?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to Verici Dx?

Summary

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, ABDX, GDR, YGEN, and VRCI

How does Diaceutics compare to Integrated Diagnostics?

Is IDHC or DXRX more profitable?

Does the media favor IDHC or DXRX?

Which has more volatility and risk, IDHC or DXRX?

Do analysts prefer IDHC or DXRX?

Which has higher earnings and valuation, IDHC or DXRX?

Do institutionals and insiders hold more shares of IDHC or DXRX?

Summary

How does Diaceutics compare to Abingdon Health?

Which has preferable valuation and earnings, ABDX or DXRX?

Is ABDX or DXRX more profitable?

Does the media refer more to ABDX or DXRX?

Which has more risk & volatility, ABDX or DXRX?

Do analysts prefer ABDX or DXRX?

Do institutionals & insiders hold more shares of ABDX or DXRX?

Summary

How does Diaceutics compare to genedrive?

Which has higher valuation and earnings, DXRX or GDR?

Does the media prefer DXRX or GDR?

Which has more volatility & risk, DXRX or GDR?

Is DXRX or GDR more profitable?

Do institutionals & insiders believe in DXRX or GDR?

Do analysts prefer DXRX or GDR?

Summary

How does Diaceutics compare to Yourgene Health?

Do institutionals and insiders hold more shares of YGEN or DXRX?

Does the media refer more to YGEN or DXRX?

Do analysts prefer YGEN or DXRX?

Is YGEN or DXRX more profitable?

Which has more risk and volatility, YGEN or DXRX?

Which has better valuation and earnings, YGEN or DXRX?

Summary

How does Diaceutics compare to Verici Dx?

Do insiders and institutionals have more ownership in VRCI or DXRX?

Which has higher earnings and valuation, VRCI or DXRX?

Do analysts rate VRCI or DXRX?

Does the media refer more to VRCI or DXRX?

Which has more volatility and risk, VRCI or DXRX?

Is VRCI or DXRX more profitable?

Summary

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools